BILLERICA, Mass. & BRISBANE, QLD--(BUSINESS WIRE)--Bruker Daltonics and the Queensland Institute of Medical Research (QIMR) announced today the installation of the first maXis™ Ultra-High Resolution Time-Of-Flight (UHR-TOF) mass spectrometer in Australasia, thereby further strengthening the collaboration between Bruker and one of the premier medical research institutes in Australia.
maXis is the only instrument available today that uniquely combines the previously incompatible trends in modern mass spectrometry of ultra-high resolution and very fast chromatographic separations. Exceptional mass accuracy, high resolution and sensitivity are maintained even when coupled to the fastest liquid chromatography systems. maXis has already been proven as an exceptional tool in quantitative proteomics, peptide and intact protein analysis as well as on-the-fly unambiguous small molecule identification using the unique Smartformula™ 3D method.
“Bruker is delighted to further strengthen the collaborative relationship we have developed with Professor Gorman and QIMR. The installation of maXis, the first in Australasia, offers a major opportunity for us to co-develop the advanced methodologies required for the wide range of applications undertaken at QIMR’s Protein Discovery Centre (PDC),” stated Clive Seymour, Executive Vice President of Bruker Daltonics.
“The installation of maXis will allow us to collaborate more extensively with Bruker, particularly in the development of ETD methodologies for the study of post-translational modifications on this exciting new platform, and represents a quantum leap in MS capability at QIMR,” commented Professor Jeff Gorman, Director of the PDC. He continued: “maXis completes the stable of high resolution mass spectrometers within the facility and is a brand new technology advancing Australian science at QIMR. maXis will add significantly to the capability of the PDC to participate in the Australian government National Collaborative Research Infrastructure Scheme, funded through Bioplatforms Australia and the Queensland Government. In particular, it will provide the PDC with the scope to collaborate more effectively with scientists from QIMR, Australia and internationally on projects aimed at combating infectious diseases and cancer.”
For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR - News), please visit www.bdal.com and www.bruker.com.
Contact:
Bruker Daltonics Inc. Clive Seymour, +64 21 640 801 Executive Vice President chs@bdal.com
Source: Bruker Corporation
